BBIO - Rare Disease Player BridgeBio Pharma's Upside Potential Is Significant According to Citi Analyst - Here's Why | Benzinga
Citi initiated coverage on BridgeBio Pharma Inc (NASDAQ: BBIO), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, noting an optimistic outlook on the stock.
The analyst David Lebowitz says the optimistic outlook stems from the substantial market potential of acoramidis, particularly following its recent Phase 3 successes in treating ATTR cardiomyopathy (ATTR-CM).
ATTR-CM primarily affects the heart, as clumps of amyloid are deposited in the heart tissue.